Hermann L S, Melander A
Meda AB, Göteborg.
Lakartidningen. 1999 Dec 15;96(50):5616-9.
Type II diabetes patients on insulin often show inadequate glycaemic control and weight gain. The rationale for adding metformin in these cases is that it can reduce insulin resistance. The present article reviews the growing body of clinical documentation supporting combination therapy, i.e. placebo-controlled studies in insulin-treated patients and controlled studies with reference therapies in patients not yet treated with insulin. These studies show improvement of glycaemic control and less weight gain. Insulin dosages can be reduced in both type II and type I diabetes. A combination of insulin and metformin is recommended especially for obese type II diabetes patients on high insulin doses.
使用胰岛素治疗的II型糖尿病患者常常血糖控制不佳且体重增加。在这些情况下加用二甲双胍的理论依据是它可以降低胰岛素抵抗。本文综述了支持联合治疗的越来越多的临床文献，即在接受胰岛素治疗的患者中进行的安慰剂对照研究以及在尚未接受胰岛素治疗的患者中使用对照疗法的对照研究。这些研究表明血糖控制得到改善且体重增加较少。II型和I型糖尿病患者的胰岛素剂量均可减少。尤其对于使用高剂量胰岛素的肥胖II型糖尿病患者，推荐胰岛素与二甲双胍联合使用。
